Two days of exceptional programming and networking anchored by 28 oncology companies. Attending investors heard insights from Jack Hidary Google Artificial Intelligence strategist provided insight on the future role of AI treating Cancer. Dr. Sujuan Ba, President of National Foundation for Cancer Research gave outlook on Cancer research. Prolific biotech investor and Celgene founder Isaac Blech described keys to success in early biotech Investing. Aisling Capital, Founder Dennis Purcell described the development of new financial instruments, specifically a futures market for managing risk in the healthcare sector. Former J&J executive Lili Gil Valletta, presented on how big data and AI tools can uncover weaknesses in the delivery…
Browsing: Uncategorized
Cervical Cancer Cervical cancer continues to affect women of all ages worldwide. The disease often presents no symptoms in its early stages, which is why it is often referred to as a “silent killer.” Most cervical cancers are caused by the human papillomavirus (HPV), a common virus that can be passed from one person to another through sexual activity. With the advent of the HPV vaccine and regular Pap screening tests, most cervical cancers can now be prevented. In 2017, it is estimated that nearly 13,000 women will be diagnosed with invasive cervical cancer in the U.S. and more than…
Breast Cancer Breast cancer is the most common cancer in women worldwide, claiming the lives of hundreds of thousands of women each year. Although it’s rare, men can also be diagnosed with breast cancer. With breast cancer continuing to impact so many people, it’s important to understand the disease and what strides researchers are making. More than 3.1 million breast cancer survivors live in the U.S. today. The lifetime risk of getting breast cancer in the U.S. is about 1 in 8 for women and 1 in 1,000 for men. Research shows only 5-10% of breast cancers are hereditary. Dense…
ALISO VIEJO, Calif. & SAVANNAH, Ga.–(BUSINESS WIRE)–Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, and Health Discovery Corporation (HDC) (OTCBB: HDVY) a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development, today announced that the companies have completed the three-phased, double-blind clinical validation studies for their new gene-based molecular diagnostic test for prostate cancer. Results from Phase I, Phase II and Phase III double-blinded clinical validation studies on prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center…
Head & Neck Cancer Report Launched The first chapter of the Cancer Impact Guide includes an overall summary of the current approach to diagnosis and standard of care and profiles of companies. Visit the Head and Neck section of the Cancer Impact Guide. Several promising public companies with catalysts on the horizon were identified including CEL-SCI, Soligenix and CytRx all who have become members of the Cancer Consortium, a global effort to increase collaboration of organizations of all types to advance progress in cancer. Head and neck cancer researchers around the globe continue to make steady progress toward developing effective…
Company Successfully Transfers T-Cell Receptor Genetic Material into Human Hematopoietic Stem Cells ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical stage immuno-oncology company, has achieved an important milestone toward initiating pre-clinical trials of its Stem-to-T-Cell approach to cancer therapy. ImmunoCellular Therapeutics has verified the successful transfer of selected T-cell receptor genetic material into human hematopoietic stem cells. This milestone is a key component of the ongoing proof-of-concept work that ImmunoCellular Therapeutics is conducting for its Stem-to-T-Cell technology. Steven J. Swanson, PhD, ImmunoCellular Therapeutics’ Senior Vice President of Research, stated, “We are excited to have achieved this critical next milestone in our…
Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical needs, has recently appointed two world-reknowned oncologists to its Medical Advisory Board. Dr. George Sledge is Professor and Chief of the Division of Oncology at Stanford University Medical Center. Dr. Razelle Kurzrock is Professor and Chief of the Division of Hematology & Oncology at UCSD Moores Cancer Center. Both Drs. Sledge and Kurzrock will provide Immix Biopharma with strategic guidance and insights on critical unmet areas of need…
Initiated by a global think tank, Klosters Institute, the objective is to create a consortium committed to fostering collaboration. Research to assessing connectivity the global cancer ecosystem and published in a Cancer Impact Guide targeted at family offices, foundations and impact investors. Initiated by a global think tank, Klosters Institute, the objective is to create a consortium committed to fostering collaboration and initially presented at the New York Oncology Conference May 8 and 9 Conference will feature a global update on progress in oncology highly screened group of companies and key opinion leaders in the field of oncology. Commissioned by…